MicroRNA-Based Methods and Assays for Osteosarcoma
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 3 of these applications claim priority to application PCT/IB2012/002626, filed Sep 7, 2012. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 10,905,708 | Microrna-Based Methods and Assays for Osteocarcinoma In force · High confidence | 3-D Matrix, Ltd. | In force | High confidence | ||
| US 11,260,072 | MicroRNA-based methods and assays for osteocarcinoma In force · High confidence | 3-D Matrix, Ltd. | In force | High confidence | ||
| US 9,322,016 | MicroRNA-Based Methods and Assays for Osteosarcoma In force · High confidence | 3-D Matrix, Ltd. | In force | High confidence | ||
| Application 15/096,480 | MicroRNA-Based Methods and Assays for Osteosarcoma Abandoned Abandoned Aug 5, 2019 | 3-D Matrix, Ltd. | Abandoned | Abandoned Aug 5, 2019 |
4 of 4 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
3 of these are in force and held by 3-D Matrix, Ltd..
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.